# Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)

> **NCT00502788** · PHASE2 · COMPLETED · sponsor: **Carelon Research** · enrollment: 21 (actual)

## Conditions studied

- Hepatitis C
- Thalassemia

## Interventions

- **DRUG:** Peginterferon Alfa-2a and Ribavirin
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00502788
- **Lead sponsor:** Carelon Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2006-06
- **Final completion:** 2006-08
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2014-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00502788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00502788, "Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00502788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*